Table 1.
Linear clearance rate estimates with residual standard error (RSE) reported for 64 therapeutic antibodies. XI, ZU & HU indicate chimeric, humanized or human origin. aAntibody drug conjugate, bpegylated Fab
| mAb | Clearance (mL/day/kg) | RSE | Isotype | Origin | mAb | Clearance (mL/day/kg) | RSE | Isotype | Origin | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abituzumab | 3.52 | 2.63 | G2 | ZU | Guselkumab | 4.35 | 0.31 | G1 | HU | ||
| Adalimumab | 3.66 | 0.40 | G1 | HU | Infliximab | 3.62 | 0.48 | G1 | XI | ||
| Alirocumab | 3.16 | 0.28 | G1 | HU | Ipilimumab | 4.46 | 0.43 | G1 | HU | ||
| Atezolizumab | 2.70 | 1.20 | G1 | ZU | Matuzumab | 5.58 | 1.87 | G1 | ZU | ||
| Basiliximab | 11.34 | 1.00 | G1 | XI | Mavrilimumab | 4.33 | 0.32 | G4 | HU | ||
| Bavituximab | 31.22 | 0.74 | G1 | XI | Mepolizumab | 2.48 | 0.26 | G1 | ZU | ||
| Belimumab | 2.95 | 0.23 | G1 | HU | Natalizumab | 7.09 | 1.82 | G4 | ZU | ||
| Bevacizumab | 2.99 | 0.40 | G1 | ZU | Necitumumab | 2.35 | 1.11 | G1 | HU | ||
| Brentuximab vedotina | 22.19 | 0.40 | G1 | XI | Nimotuzumab | 4.64 | 1.44 | G1 | ZU | ||
| Brodalumab | 2.99 | 0.01 | G2 | HU | Nivolumab | 3.32 | 0.96 | G4 | HU | ||
| Canakinumab | 2.18 | 0.35 | G1 | HU | Obinutuzumab | 0.85 | 0.82 | G1 | ZU | ||
| Carlumab | 12.82 | 1.30 | G1 | HU | Ofatumumab | 2.90 | 2.51 | G1 | HU | ||
| Certolizumab pegolb | 3.37 | 0.14 | G1 | ZU | Onartuzumab | 6.96 | 0.03 | G1 | ZU | ||
| Cetuximab | 7.88 | 1.32 | G1 | XI | Pembrolizumab | 3.16 | 0.07 | G4 | ZU | ||
| Cixutumumab | 3.25 | 0.81 | G1 | HU | Pertuzumab | 3.29 | 0.46 | G1 | ZU | ||
| Daclizumab | 2.05 | 0.98 | G1 | ZU | Ponezumab | 2.12 | 0.23 | G2 | ZU | ||
| Dalotuzumab | 7.42 | 0.93 | G1 | ZU | Ramucirumab | 3.01 | 1.00 | G1 | HU | ||
| Daratumumab | 1.60 | 1.64 | G1 | HU | Reslizumab | 2.49 | 0.37 | G4 | ZU | ||
| Duligotuzumab | 6.38 | 0.44 | G1 | ZU | Rilotumumab | 2.76 | 0.29 | G2 | HU | ||
| Eculizumab | 7.04 | 1.26 | G2 | ZU | Rituximab | 2.96 | 1.70 | G1 | XI | ||
| Efalizumab | 0.50 | 176 | G1 | ZU | Secukinumab | 2.02 | 0.36 | G1 | HU | ||
| Eldelumab | 5.54 | 0.47 | G1 | HU | Sifalimumab | 2.55 | 0.18 | G1 | HU | ||
| Elotuzumab | 5.95 | 1.06 | G1 | ZU | Siltuximab | 4.00 | 0.79 | G1 | XI | ||
| Emibetuzumab | 4.02 | 0.19 | G4 | ZU | Sirukumab | 5.56 | 0.30 | G1 | HU | ||
| Etrolizumab | 3.56 | 0.16 | G1 | ZU | Tabalumab | 1.70 | 1.67 | G4 | HU | ||
| Evolocumab | 2.86 | 0.03 | G2 | HU | Tanezumab | 2.45 | 0.30 | G2 | ZU | ||
| Farletuzumab | 2.87 | 0.43 | G1 | ZU | Tigatuzumab | 4.90 | 0.50 | G1 | ZU | ||
| Ficlatuzumab | 5.07 | 0.47 | G1 | ZU | Tocilizumab | 4.66 | 0.85 | G1 | ZU | ||
| Figitumumab | 4.20 | 1.36 | G2 | HU | Trastuzumab | 2.76 | 1.49 | G1 | ZU | ||
| Ganitumab | 12.59 | 1.34 | G1 | HU | Tremelimumab | 3.45 | 0.27 | G2 | HU | ||
| Girentuximab | 5.23 | 0.75 | G1 | XI | Vedolizumab | 2.10 | 2.18 | G1 | ZU | ||
| Golimumab | 6.47 | 0.36 | G1 | HU | Veltuzumab | 1.00 | 0.54 | G1 | ZU | ||